PE Deals Logo
PE Deals UK M&A Brokers & VC
Back to Deals
Veremark
Value £19,000,000

Veremark

VC Funding
Series B
Healthcare & Biotech Published 3 February 2026

Summary

Veremark, a London-based technology provider specializing in background checks and applicant screening, has successfully raised £19 million in a Series B funding round. The investment was led by Gresham House Ventures, with additional participation from existing investors Samaipata, ACF Investors, and Stage 2 Capital, and includes a multi-million debt facility from Salica Partners. This funding is earmarked to facilitate Veremark's global expansion and drive further investment into new products and AI development.

Summary of transaction details:

  • Value: £19 million
  • Sector: HR Technology, Background Screening, AI
  • Advisor: N/A
  • Key Entities: Veremark (Target Company), Gresham House Ventures (Lead Investor), Samaipata, ACF Investors, Stage 2 Capital, Salica Partners (Participating Investors)
  • Location: London (Veremark Headquarters)

Note: The funding will enable Veremark to capitalize on the increasing market demand for stronger workplace trust initiatives and advanced verification tools, particularly given the challenges posed by a dynamic global workforce and the growing use of AI in presenting false data or profiles. Veremark aims to scale its platform globally, enhance client experience, and continue setting the standard for managing workplace trust.

Lead Investor / Acquirer

Gresham House Ventures

Advising Broker

Undisclosed Firm

Original Source

View the original press release or news article describing this transaction in full.

Read Original Post

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Sign in to unlock AI Lenses

Sign in

Sign in to submit corrections

Free to all registered users.